{"id":15964,"date":"2023-07-21T00:24:00","date_gmt":"2023-07-20T16:24:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15964"},"modified":"2024-12-01T00:26:07","modified_gmt":"2024-11-30T16:26:07","slug":"abbott-reports-q2-2023-revenue-growth-exceeding-estimates-despite-covid-19-dip","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15964","title":{"rendered":"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip"},"content":{"rendered":"\n

US-based life sciences firm Abbott (NYSE: ABT<\/a>) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts’ consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in Q2\u201923, the company’s total sales were down -9.2% year-on-year (YOY) in constant currency terms to USD 9.978 billion. However, this performance outperformed analyst forecasts, and excluding the impact of COVID-related sales, underlying total revenues grew at an impressive 11.5% YOY.<\/p>\n\n\n\n

Strong Performance Across Core Business Units<\/strong>
Abbott’s core business units, including nutrition, diagnostics, pharmaceuticals, and medical devices, showed strong performance. Excluding the impact of COVID-related products, medical device sales rose 14% to USD 4.3 billion, diagnostics sales increased 7.1% to USD 2.317 billion, nutrition sales grew 9.9% to USD 2.076 billion, and pharmaceuticals sales rose 12.6% to USD 1.287 billion. This demonstrates the company’s ability to drive growth across its diversified portfolio.<\/p>\n\n\n\n

Growth in US and International Markets<\/strong>
Both US and International markets contributed to Abbott’s growth, with the US generating USD 3.758 billion in total sales, up 10.9%, and International markets generating USD 6.2 billion, up 11.9%. This broad-based positive performance across geographies highlights the company’s global reach and market penetration.<\/p>\n\n\n\n

CEO’s Comments and Full-Year Guidance Update<\/strong>
During the earnings conference call, CEO Robert Ford expressed his satisfaction with the top-line performance, stating it is “very sustainable.” As a result, the full-year guidance for revenue growth was raised to low double-digit from high single-digit previously, reflecting the company’s confidence in its growth trajectory.<\/p>\n\n\n\n

China’s Role as a Growth Driver<\/strong>
China was identified as one of the leading growth drivers in the sales of Established Pharmaceuticals, Diagnostics, and electrophysiology. This underscores the importance of the Chinese market in Abbott’s global strategy and its contribution to the company’s overall growth.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[503,27,870],"class_list":["post-15964","post","type-post","status-publish","format-standard","hentry","category-company","tag-abbott","tag-finanical-reports","tag-nyse-abt"],"yoast_head":"\nAbbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts' consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in Q2\u201923, the company's total sales were down -9.2% year-on-year (YOY) in constant currency terms to USD 9.978 billion. However, this performance outperformed analyst forecasts, and excluding the impact of COVID-related sales, underlying total revenues grew at an impressive 11.5% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15964\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15964\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-20T16:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-30T16:26:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15964#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15964\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip\",\"datePublished\":\"2023-07-20T16:24:00+00:00\",\"dateModified\":\"2024-11-30T16:26:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15964\"},\"wordCount\":316,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbott\",\"Finanical Reports\",\"NYSE: ABT\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15964#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15964\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15964\",\"name\":\"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-20T16:24:00+00:00\",\"dateModified\":\"2024-11-30T16:26:07+00:00\",\"description\":\"US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts' consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in Q2\u201923, the company's total sales were down -9.2% year-on-year (YOY) in constant currency terms to USD 9.978 billion. However, this performance outperformed analyst forecasts, and excluding the impact of COVID-related sales, underlying total revenues grew at an impressive 11.5% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15964#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15964\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15964#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip - Insight, China's Pharmaceutical Industry","description":"US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts' consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in Q2\u201923, the company's total sales were down -9.2% year-on-year (YOY) in constant currency terms to USD 9.978 billion. However, this performance outperformed analyst forecasts, and excluding the impact of COVID-related sales, underlying total revenues grew at an impressive 11.5% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15964","og_locale":"en_US","og_type":"article","og_title":"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15964","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-20T16:24:00+00:00","article_modified_time":"2024-11-30T16:26:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15964#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15964"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip","datePublished":"2023-07-20T16:24:00+00:00","dateModified":"2024-11-30T16:26:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15964"},"wordCount":316,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbott","Finanical Reports","NYSE: ABT"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15964#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15964","url":"https:\/\/flcube.com\/?p=15964","name":"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-20T16:24:00+00:00","dateModified":"2024-11-30T16:26:07+00:00","description":"US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts' consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in Q2\u201923, the company's total sales were down -9.2% year-on-year (YOY) in constant currency terms to USD 9.978 billion. However, this performance outperformed analyst forecasts, and excluding the impact of COVID-related sales, underlying total revenues grew at an impressive 11.5% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15964#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15964"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15964#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15964"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15964\/revisions"}],"predecessor-version":[{"id":15965,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15964\/revisions\/15965"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}